Home > Oncology > ESMO 2021 > Melanoma > IFN-γ signature predicts response to immunotherapy

IFN-γ signature predicts response to immunotherapy

Presented By
Prof. Christian Blank, Netherlands Cancer Institute, the Netherlands

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ESMO 2021
Trial
Phase 1, DONIMI
Preliminary results of the phase 1b DONIMI trial showed that the interferon (IFN)-γ signature is useful to discriminate between melanoma patients who will benefit from neoadjuvant therapy with nivolumab alone and patients who might need an escalated therapy. Neoadjuvant immunotherapy with ipilimumab plus nivolumab induces high pathologic response rates (72–78%) in stage IIIB-D melanoma and is strongly associated with long-term relapse-free survival (RFS) [1]. Patients with a low baseline IFN-γ signature are known to be less likely to respond to immunotherapy [2]. The class I histone deacetylase inhibitor domatinostat has previously demonstrated to increase intertumoral T-cell infiltration and IFN-γ sign expression in melanoma. The DONIMI trial (NCT04133948) tests neoadjuvant combinations of nivolumab plus ipilimumab with domatinostat in melanoma patients stratified...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on